Published in World J Gastroenterol on October 21, 2014
Spironolactone Therapy In Young Women With NASH | NCT03576755
P2X7 receptor as a key player in oxidative stress-driven cell fate in nonalcoholic steatohepatitis. Oxid Med Cell Longev (2015) 0.81
NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment. Am J Pathol (2015) 0.81
Endocrine causes of nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.79
Sex Hormones and Their Receptors Regulate Liver Energy Homeostasis. Int J Endocrinol (2015) 0.79
Relevance of low testosterone to non-alcoholic fatty liver disease. Cardiovasc Endocrinol (2015) 0.77
Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? World J Gastroenterol (2016) 0.76
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis. J Clin Gastroenterol (2017) 0.75
Hepcidin in non-alcoholic fatty liver disease regulated by the TLR4/NF-κB signaling pathway. Exp Ther Med (2015) 0.75
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep (2016) 0.75
Omic studies reveal the pathogenic lipid droplet proteins in non-alcoholic fatty liver disease. Protein Cell (2016) 0.75
Omega-3 supplementation effects on polycystic ovary syndrome symptoms and metabolic syndrome. J Res Med Sci (2017) 0.75
Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest (2017) 0.75
Nonalcoholic fatty liver disease. N Engl J Med (2002) 22.41
The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology (2005) 15.74
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril (2004) 12.87
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med (2002) 10.78
Thiazolidinediones. N Engl J Med (2004) 9.42
Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology (2006) 9.34
The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol (2003) 8.23
The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab (2004) 7.96
Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther (2011) 7.91
Nonalcoholic steatohepatitis. Ann Intern Med (1997) 5.74
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab (2006) 4.56
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod (2009) 3.74
Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes (1989) 3.74
The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology (1995) 3.73
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol (2006) 3.62
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA (2003) 3.51
Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA (2011) 3.37
The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol (2003) 3.04
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab (2001) 2.66
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2013) 2.43
Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology (2008) 2.36
Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia (2008) 2.32
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004. Gastroenterology (2007) 2.22
Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med (2010) 2.21
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia (2012) 1.98
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology (2000) 1.96
Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatol (2011) 1.94
Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update (2010) 1.86
Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril (2008) 1.78
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol (2007) 1.78
Apnoeic-hypopnoeic episodes during obstructive sleep apnoea are associated with histological nonalcoholic steatohepatitis. Liver Int (2008) 1.74
Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol (2008) 1.71
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol (2011) 1.69
Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol (2008) 1.68
The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep (2005) 1.66
Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod (2013) 1.55
Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes (1992) 1.54
The paradox of progress: environmental disruption of metabolism and the diabetes epidemic. Diabetes (2011) 1.49
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. Clin Endocrinol (Oxf) (2011) 1.45
Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab (1986) 1.43
Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol (2007) 1.43
Chronic liver injury during obstructive sleep apnea. Hepatology (2005) 1.39
Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther (2012) 1.37
Prevalence, gender, ethnic variations, and prognosis of NASH. J Gastroenterol (2010) 1.29
Nonalcoholic fatty liver disease as a complication of insulin resistance. Med Clin North Am (2007) 1.29
Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med (2006) 1.27
Prognosis of patients with a diagnosis of fatty liver--a registry-based cohort study. Hepatogastroenterology (2003) 1.24
Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol (2013) 1.22
Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev (2011) 1.22
Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol (2010) 1.21
Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab (2010) 1.21
Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis (2009) 1.21
Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol (2014) 1.20
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev (2007) 1.18
Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism. Hepatology (2012) 1.14
Spleen enlargement in patients with nonalcoholic fatty liver: correlation between degree of fatty infiltration in liver and size of spleen. Dig Dis Sci (2000) 1.12
Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 1.11
The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. Fertil Steril (2010) 1.09
Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2011) 1.07
Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab (2009) 1.07
Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab (2012) 1.06
Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev (2012) 1.05
Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03
Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev (2007) 1.02
Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol (2001) 1.02
Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod (2009) 1.02
The adipose cell lineage is not intrinsically insulin resistant in polycystic ovary syndrome. Metabolism (2007) 1.00
Body fat topography as an independent predictor of fatty liver. Metabolism (1993) 0.98
The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg (2006) 0.98
Bisphenol A in polycystic ovary syndrome and its association with liver-spleen axis. Clin Endocrinol (Oxf) (2013) 0.98
Obstructive sleep apnea is associated with fatty liver and abnormal liver enzymes: a meta-analysis. Obes Surg (2013) 0.97
Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab (1990) 0.96
Global adiposity and thickness of intraperitoneal and mesenteric adipose tissue depots are increased in women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab (2013) 0.96
Can persistent organic pollutants and plastic-associated chemicals cause cardiovascular disease? J Intern Med (2012) 0.96
Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep (2011) 0.95
An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. J Gastroenterol Hepatol (2009) 0.95
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther (2013) 0.95
Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology (1997) 0.93
Hyperinsulinemia in hyperthecosis of the ovaries. Am J Obstet Gynecol (1986) 0.92
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract (2008) 0.91
Comparison of aerobic exercise capacity and muscle strength in overweight women with and without polycystic ovary syndrome. BJOG (2009) 0.90
Traditional Chinese medicines benefit to nonalcoholic fatty liver disease: a systematic review and meta-analysis. Mol Biol Rep (2012) 0.90
Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines. Minerva Ginecol (2004) 0.89
Fatty liver index in polycystic ovary syndrome. Eur J Endocrinol (2011) 0.88
Molecular signature of adipose tissue in patients with both non-alcoholic fatty liver disease (NAFLD) and polycystic ovarian syndrome (PCOS). J Transl Med (2013) 0.88
Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab (2009) 0.87
Serum resistin and adiponectin levels in women with polycystic ovary syndrome. Gynecol Endocrinol (2009) 0.87
Abnormal aminotransferase activity in women with polycystic ovary syndrome. Fertil Steril (2005) 0.87
Phenotypes and enviromental factors: their influence in PCOS. Curr Pharm Des (2012) 0.86